Latigo Biotherapeutics In... (LTGO)
El precio, las cifras principales y las últimas noticias, en un solo sitio.
Latigo Biotherapeutics Inc. (LTGO): cotización, análisis y datos
| Precio de compra | 24.39 |
| Capitalización de mercado | 1.53B |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -111.18M |
| n/a | |
| -2.47 | |
| n/a | |
| n/a | |
| P/B (TTM) | -0.57 |
| P/S (TTM) | n/a |
| Fecha de resultados | n/a |
| Precio de venta | 24.77 |
| Volumen | 217,740 |
| Volumen medio (20D) | 423,375 |
| Abierto | 25.21 |
| Anterior Cerrar | 25.00 |
| Rango del día | 24.23 - 25.62 |
| Rango de 52 semanas | 17.22 - 25.93 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de LTGO
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibito...
Desempeño financiero
En 2025, los ingresos de Latigo Biotherapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -109.17M, un aumento de 78.43%.
Estados financieros
2 semanas hace · 24/7 Wall St.
Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes PublicA California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science ...
3 semanas hace · Simply Wall St.
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right ValuedLatigo Biotherapeutics (LTGO) recently raised US$345.6 million in its IPO, offering 19,200,000 common shares at US$18 each, following publication in the New England Journal of Medicine of clinical dat...